3.8
CiteScore
2.4
Impact Factor
- ISSN 1674-8301
- CN 32-1810/R
3.8
2.4
| Citation: |
Xinlu Chai, Yuting Meng, Wei Ge, Juan Wang, Fei Li, Xue Jun Wang, Xuerong Wang. A novel synthesized prodrug of gemcitabine based on oxygen-free radical sensitivity inhibited the growth of lung cancer cells[J]. The Journal of Biomedical Research, 2023, 37(5): 355-366. DOI: 10.7555/JBR.37.20230022
|
In the present study, we introduced the H2O2-sensitive thiazolidinone moiety at the 4th amino group of gemcitabine (GEM) to synthesize a new target compound named GEM-ZZQ, and then we confirmed its chemical structure by nuclear magnetic resonance spectroscopy. We further confirmed that GEM-ZZQ had a good chemical stability in different pH solutions in vitro and that it could be activated by H2O2 to release GEM. Pharmacodynamic studies revealed that the growth inhibition of human normal epithelial cells was weaker by GEM-ZZQ than by GEM treatment and that the inhibition of various lung cancer cell lines by GEM-ZZQ was similar to that of GEM. For the lung cancer cell lines that are resistant to the epidermal growth factor receptor (EGFR)-targeting inhibitor osimertinib, GEM-ZZQ showed less growth inhibition than GEM; however, GEM-ZZQ in combination with cisplatin showed better synergistic effects than GEM in the low-dose groups. In summary, we provided a new anti-cancer compound GEM-ZZQ for treating lung cancer by modifying the GEM structure.
This work was supported by the National Natural Science Foundation of China (Grant Nos. 81972763 and 81473241).
We acknowledge and appreciate our colleagues for their valuable efforts and comments on this paper.
CLC number: R966, Document code: A
The authors reported no conflict of interests.
| [1] |
Heinemann V, Xu Y, Chubb S, et al. Cellular elimination of 2', 2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation[J]. Cancer Res, 1992, 52(3): 533–539. https://typeset.io/papers/cellular-elimination-of-2-2-difluorodeoxycytidine-5-31nzxo1c13
|
| [2] |
Eckel F, Schneider G, Schmid RM. Pancreatic cancer: a review of recent advances[J]. Expert Opin Investig Drugs, 2006, 15(11): 1395–1410. doi: 10.1517/13543784.15.11.1395
|
| [3] |
Ueno H, Kiyosawa K, Kaniwa N. Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?[J]. Br J Cancer, 2007, 97(2): 145–151. doi: 10.1038/sj.bjc.6603860
|
| [4] |
Plunkett W, Huang P, Xu Y, et al. Gemcitabine: metabolism, mechanisms of action, and self-potentiation[J]. Semin Oncol, 1995, 22(4 Suppl 11): 3–10. https://pubmed.ncbi.nlm.nih.gov/7481842/
|
| [5] |
Immordino ML, Brusa P, Rocco F, et al. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs[J]. J Controlled Release, 2004, 100(3): 331–346. doi: 10.1016/j.jconrel.2004.09.001
|
| [6] |
Albert A. Chemical aspects of selective toxicity[J]. Nature, 1958, 182(4633): 421–423. doi: 10.1038/182421a0
|
| [7] |
Kapacee ZA, Knox JJ, Palmer D, et al. NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials[J]. Med Oncol, 2020, 37(7): 61. doi: 10.1007/s12032-020-01386-6
|
| [8] |
Huttunen KM, Rautio J. Prodrugs - an efficient way to breach delivery and targeting barriers[J]. Curr Top Med Chem, 2011, 11(18): 2265–2287. doi: 10.2174/156802611797183230
|
| [9] |
Mahato R, Tai W, Cheng K. Prodrugs for improving tumor targetability and efficiency[J]. Adv Drug Deliv Rev, 2011, 63(8): 659–670. doi: 10.1016/j.addr.2011.02.002
|
| [10] |
Ettmayer P, Amidon GL, Clement B, et al. Lessons learned from marketed and investigational prodrugs[J]. J Med Chem, 2004, 47(10): 2393–2404. doi: 10.1021/jm0303812
|
| [11] |
Kumar R, Han J, Lim HJ, et al. Mitochondrial induced and self-monitored intrinsic apoptosis by antitumor theranostic prodrug: in vivo imaging and precise cancer treatment[J]. J Am Chem Soc, 2014, 136(51): 17836–17843. doi: 10.1021/ja510421q
|
| [12] |
Zhou J, Nie R, Yin Y, et al. Protective effect of natural antioxidants on reducing cisplatin-induced nephrotoxicity[J]. Dis Markers, 2022, 2022: 1612348. doi: 10.1155/2022/1612348
|
| [13] |
Szatrowski TP, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells[J]. Cancer Res, 1991, 51(3): 794–798. https://pubmed.ncbi.nlm.nih.gov/1846317/
|
| [14] |
Xie X, Yang X, Wu T, et al. Rational design of an α-ketoamide-based near-infrared fluorescent probe specific for hydrogen peroxide in living systems[J]. Anal Chem, 2016, 88(16): 8019–8025. doi: 10.1021/acs.analchem.6b01256
|
| [15] |
Zhou X, Sun T, Meng Y, et al. BET inhibitors combined with chemotherapy synergistically inhibit the growth of NSCLC cells[J]. Oncol Rep, 2021, 45(5): 70. doi: 10.3892/or.2021.8021
|
| [16] |
Wang X, Yue P, Kim YA, et al. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation[J]. Cancer Res, 2008, 68(18): 7409–7418. doi: 10.1158/0008-5472.CAN-08-1522
|
| [17] |
Xu K, Sun G, Li M, et al. Glibenclamide targets sulfonylurea receptor 1 to inhibit p70S6K activity and upregulate KLF4 expression to suppress non-small cell lung carcinoma[J]. Mol Cancer Ther, 2019, 18(11): 2085–2096. doi: 10.1158/1535-7163.MCT-18-1181
|
| [18] |
Chou T. The combination index (CI < 1) as the definition of synergism and of synergy claims[J]. Synergy, 2018, 7: 49–50. doi: 10.1016/j.synres.2018.04.001
|
| [19] |
Pereira M, Vale N. Repurposing alone and in combination of the antiviral saquinavir with 5-fluorouracil in prostate and lung cancer cells[J]. Int J Mol Sci, 2022, 23(20): 12240. doi: 10.3390/ijms232012240
|
| [20] |
Moloney JN, Cotter TG. ROS signalling in the biology of cancer[J]. Semin Cell Dev Biol, 2018, 80: 50–64. doi: 10.1016/j.semcdb.2017.05.023
|
| [21] |
Shi Y, Au JSK, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)[J]. J Thorac Oncol, 2014, 9(2): 154–162. doi: 10.1097/JTO.0000000000000033
|
| [22] |
Harrison PT, Vyse S, Huang PH. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer[J]. Semin Cancer Biol, 2020, 61: 167–179. doi: 10.1016/j.semcancer.2019.09.015
|
| [23] |
Leonetti A, Sharma S, Minari R, et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer[J]. Br J Cancer, 2019, 121(9): 725–737. doi: 10.1038/s41416-019-0573-8
|
| [24] |
Gorden KJ, Mesbah P, Kolesar JM. EGFR inhibitors as first-line therapy in EGFR mutation-positive patients with NSCLC[J]. J Oncol Pharm Pract, 2012, 18(2): 245–249. doi: 10.1177/1078155211408373
|
| [25] |
Zhang K, Zhang Y, Lei H, et al. Targeting AKR1B1 inhibits glutathione de novo synthesis to overcome acquired resistance to EGFR-targeted therapy in lung cancer[J]. Sci Transl Med, 2021, 13(614): eabg6428. doi: 10.1126/scitranslmed.abg6428
|
| [26] |
Hamai K, Fujitaka K, Kitaguchi S, et al. Gemcitabine maintenance therapy after gemcitabine and platinum drug chemotherapy for naive stage IIIB/IV squamous cell lung cancer: a phase II study[J]. Anticancer Drugs, 2021, 32(7): 767–772. https://pubmed.ncbi.nlm.nih.gov/33967202/
|
| [27] |
Boonsong T, Usaha S, Nakwan N, et al. Survival analysis and clinical outcomes between paclitaxel and carboplatin versus carboplatin and gemcitabine in patients with advanced-stage non-small-cell lung cancer: a single-center cohort study[J]. Asian Pac J Cancer Prev, 2022, 23(10): 3371–3378. doi: 10.31557/APJCP.2022.23.10.3371
|
| [28] |
De Mello RA, Neves NM, Tadokoro H, et al. New target therapies in advanced non-small cell lung cancer: a review of the literature and future perspectives[J]. J Clin Med, 2020, 9(11): 3543. doi: 10.3390/jcm9113543
|
| [29] |
Moysan E, Bastiat G, Benoit JP. Gemcitabine versus modified gemcitabine: a review of several promising chemical modifications[J]. Mol Pharm, 2013, 10(2): 430–444. doi: 10.1021/mp300370t
|
| [1] | Natalia V. Naryzhnaya, Leonid N. Maslov, Sergey V. Popov, Alexandr V. Mukhomezyanov, Vyacheslav V. Ryabov, Boris K. Kurbatov, Alexandra E. Gombozhapova, Nirmal Singh, Feng Fu, Jian-Ming Pei, Sergey V. Logvinov. Pyroptosis is a drug target for prevention of adverse cardiac remodeling: The crosstalk between pyroptosis, apoptosis, and autophagy[J]. The Journal of Biomedical Research, 2022, 36(6): 375-389. DOI: 10.7555/JBR.36.20220123 |
| [2] | Yong-Dae Kim, Dong-Hyuk Yim, Sang-Yong Eom, Ji Yeoun Lee, Heon Kim. The effect of sunblock against oxidative stress in farmers: a pilot study[J]. The Journal of Biomedical Research, 2017, 31(4): 344-349. DOI: 10.7555/JBR.31.20160092 |
| [3] | Iyaswamy Ashok, Rathinasamy Sheeladevi, Dapkupar Wankhar. Acute effect of aspartame-induced oxidative stress in Wistar albino rat brain[J]. The Journal of Biomedical Research, 2015, 29(5): 390-396. DOI: 10.7555/JBR.28.20120118 |
| [4] | Xiaofan Yang, Bin Sun, Huijuan Wang, Cheng Yin, Xiaole Wang, Xiaohui Ji. Increased serum IL-10 in lupus patients promotes apoptosis of T cell subsets via the caspase 8 pathway initiated by Fas signaling[J]. The Journal of Biomedical Research, 2015, 29(3): 232-240. DOI: 10.7555/JBR.29.20130037 |
| [5] | Lintao Wang, Yanyan Peng, Kaikai Shi, Haixiao Wang, Jianlei Lu, Yanli Li, Changyan Ma. Osthole inhibits proliferation of human breast cancer cells by inducing cell cycle arrest and apoptosis[J]. The Journal of Biomedical Research, 2015, 29(2): 132-138. DOI: 10.7555/JBR.27.20120115 |
| [6] | Pengpeng Jin, Xiaoli Wang, Fei Chang, Yinyang Bai, Yingchun Li, Rong Zhou, Ling Chen. Low dose bisphenol A impairs spermatogenesis by suppressing reproductive hormone production and promoting germ cell apoptosis in adult rats[J]. The Journal of Biomedical Research, 2013, 27(2): 135-144. DOI: 10.7555/JBR.27.20120076 |
| [7] | Yan Li, Yi Jiang, Yicong Wan, Lin Zhang, Weiwei Tang, Jingjing Ma, Shan Wu, Wenjun Cheng. Medroxyprogestogen enhances apoptosis of SKOV-3 cells via inhibition of the PI3K/Akt signaling pathway[J]. The Journal of Biomedical Research, 2013, 27(1): 43-50. DOI: 10.7555/JBR.27.20120051 |
| [8] | Danyang Ren, Quan Zhu, Jiantao Li, Tuanzhu Ha, Xiaohui Wang, Yuehua Li. Overexpression of angiopoietin-1 reduces doxorubicin-induced apoptosis in cardiomyocytes[J]. The Journal of Biomedical Research, 2012, 26(6): 432-438. DOI: 10.7555/JBR.26.20120006 |
| [9] | Xiaozheng Zhong, Xiaoyu Li, Lingling Qian, Yiming Xu, Yan Lu, Jing Zhang, Nan Li, Xudong Zhu, Jingjing Ben, Qing Yang, Qi Chen. Glycine attenuates myocardial ischemia-reperfusion injury by inhibiting myocardial apoptosis in rats[J]. The Journal of Biomedical Research, 2012, 26(5): 346-354. DOI: 10.7555/JBR.26.20110124 |
| [10] | Lingyun Li, Jing Chi, Feng Zhou, Dandan Guo, Fang Wang, Genyan Liu, Chun Zhang, Kun Yao. Human herpesvirus 6A induces apoptosis of HSB-2 cells via a mitochondrion-related caspase pathway[J]. The Journal of Biomedical Research, 2010, 24(6): 444-451. DOI: 10.1016/S1674-8301(10)60059-0 |
Figures(6) / Tables(4)
Supported by: Beijing Renhe Information Technology Co., Ltd. E-mail:
info@rhhz.net 
Authors and Reviewers
DownLoad: